The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers

Current Drug Targets

Volumn 10, Issue 11, 2009, Pages 1052-1060

  Bourin, Michel ^a   Chenu, Franck ^b   Hascoët, Martine ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Forced swim test (FST)

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CEVADINE; DESIPRAMINE; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; LAMOTRIGINE; MONOAMINE; MOOD STABILIZER; NEUROTOXIN; PAROXETINE; PHENYTOIN; SEROTONIN 1A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL BLOCKER; SODIUM CHANNEL;

ANTICONVULSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHANNEL GATING; COGNITIVE DEFECT; DRUG BINDING SITE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; FORCED SWIMMING TEST; HUMAN; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN CONFORMATION; RECEPTOR BLOCKING; REVIEW; SEROTONIN UPTAKE; SIDE EFFECT; SODIUM CONDUCTANCE; SODIUM CURRENT; SODIUM TRANSPORT; WEIGHT REDUCTION; AFFECT; ANIMAL; DRUG EFFECTS; PHYSIOLOGY;

AFFECT; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; SODIUM CHANNELS;

EID: 70450176548     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789735138     Document Type: Review

References (79)

1. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 63: 241-246
2. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 76: 525-535 (Pubitemid 34888412)
3. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003; 41: 13-25. (Pubitemid 37271085)
4. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 Suppl 1: 19-26. (Pubitemid 24107713)
5. Muscettola G, Goodwin FK, Potter WZ, Claeys MM, Markey SP. Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. Arch Gen Psychiatry 1978; 355: 621-625 (Pubitemid 8333775)
6. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000; 234: 428-438
7. Yang YC, Kuo CC. Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol 2002; 625: 1228-1237
8. Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry 2003; 812: 994-1007. (Pubitemid 37523911)
9. Gumilar F, Arias HR, Spitzmaul G, Bouzat C. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology 2003; 457: 964-976 (Pubitemid 37297922)
10. Choi JS, Choi BH, Ahn HS, Kim MJ, Han TH, Rhie DJ, et al. Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons. Brain Res 2004; 10182: 201-207
11. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000; 261: 13-25.
12. Goldin AL. Resurgence of sodium channel research. Annu Rev Physiol 2001; 63: 871-894
13. Armstrong CM, Bezanilla F. Currents related to movement of the gating particles of the sodium channels. Nature 1973; 2425398: 459-461
14. Armstrong CM, Bezanilla F. Charge movement associated with the opening and closing of the activation gates of the Na channels. J Gen Physiol 1974; 635: 533-552
15. Catterall WA. Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev 1992; 724 Suppl: S15-48.
16. Stuhmer W, Conti F, Suzuki H, Wang XD, Noda M, Yahagi N, et al. Structural parts involved in activation and inactivation of the sodium channel. Nature 1989; 3396226: 597-603. (Pubitemid 19174342)
17. Patton DE, West JW, Catterall WA, Goldin AL. Amino acid residues required for fast Na(+)-channel inactivation: charge neutralizations and deletions in the III-IV linker. Proc Natl Acad Sci USA 1992; 8922: 10905-10909
18. Vassilev PM, Scheuer T, Catterall WA. Identification of an intracellular peptide segment involved in sodium channel inactivation. Science 1988; 2414873: 1658-1661 (Pubitemid 18238705)
19. Catterall WA. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol 1980; 20: 15-43.
20. Ulbricht W. The effect of veratridine on excitable membranes of nerve and muscle. Ergeb Physiol 1969; 61: 18-71.
21. Lizasoain I, Knowles RG, Moncada S. Inhibition by lamotrigine of the generation of nitric oxide in rat forebrain slices. J Neurochem 1995; 642: 636-642
22. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 275: 490-497
23. Lingamaneni R, Hemmings HC, Jr. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 1999; 2762: 127-130
24. Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedebergs Arch Pharmacol 1996; 3542: 164-172 (Pubitemid 26248255)
25. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Psychopharmacology (Berl) 2005; 1801: 159-168
26. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 547: 597-606.
27. Nicholson GM, Blanche T, Mansfield K, Tran Y. Differential blockade of neuronal voltage-gated Na(+) and K(+) channels by antidepressant drugs. Eur J Pharmacol 2002; 4521: 35-48. (Pubitemid 35248122)
28. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C, 3rd. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 2841: 208-214 (Pubitemid 28109548)
29. Barber MJ, Starmer CF, Grant AO. Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites. Circ Res 1991; 693: 677-696
30. Wang GK, Russell C, Wang SY. State-dependent block of voltagegated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004; 1101- 2: 166-174
31. Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 1996; 2202: 117-120 (Pubitemid 26426598)
32. Kuo CC, Huang RC, Lou BS. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 2000; 571: 135-143
33. Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982; 1033: 401-414
34. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther 2004; 267: 951-979
35. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 2004; 6511: 1499-1504
36. Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005; 6611: 1376-1385 (Pubitemid 41779535)
37. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 Suppl 10: 28-35.
38. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 235: 484-495
39. Suppes T, Brown ES, McElroy SL, Keck PE, Jr., Nolen W, Kupka R, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 531: 95-98 (Pubitemid 29227358)
40. Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996; 295: 193-195 (Pubitemid 26315671)
41. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 602: 79-88. (Pubitemid 29104383)
42. Calabrese JR, Sachs GS, Hirschfeld RM. Efficacy and safety of lamotrigine in acute bipolar disorder: finding from three completed studies. Abstract of the 45th NCDEU, Annual Meeting, Boca Raton, FL, June 6-9 2005.
43. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 43: 207-213 (Pubitemid 34591247)
44. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000; 1573: 463-465 (Pubitemid 30145938)
45. Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 2003; 56: 464-467 (Pubitemid 38072251)
46. Xie X, Dale TJ, John VH, Cater HL, Peakman TC, Clare JJ. Electrophysiological and pharmacological properties of the human brain type IIA Na+ channel expressed in a stable mammalian cell line. Pflugers Arch 2001; 4414: 425-433 (Pubitemid 32128138)
47. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 2292: 327-336 (Pubitemid 8225714)
48. Prica C, Hascoet M, Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav Brain Res 2008; 1911: 49-54.
49. Bourin M, Masse F, Hascoet M. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci 2005; 304: 275-282 (Pubitemid 41243295)
50. Bourin M, Prica C. The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. Neurosci Biobehav Rev 2007; 316: 963-975 (Pubitemid 47285346)
51. Kuo CC, Lu L. Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 1997; 1216: 1231-1238 (Pubitemid 27303595)
52. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5- hydroxytryptamine uptake in rats. Eur J Pharmacol 1998; 3581: 19-24.
53. Codagnone FT, Consoni FT, Rodrigues AL, Vital MA, Andreatini R. Veratrine blocks the lamotrigine-induced swimming increase and immobility decrease in the modified forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2007; 316: 1307-1311 (Pubitemid 47086362)
54. Consoni FT, Vital MA, Andreatini R. Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol 2006; 166: 451-458 (Pubitemid 43996884)
55. Redrobe JP, Pinot P, Bourin M. The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol 1996; 106: 524-528 (Pubitemid 26403134)
56. Prakriya M, Mennerick S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000; 263: 671-682 (Pubitemid 30953908)
57. Sitges M, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology 2007; 537: 854-862 (Pubitemid 350027740)
58. Sitges M, Chiu LM, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 2007; 522: 598-605. (Pubitemid 46151686)
59. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 75: 426-437 (Pubitemid 351619114)
60. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000; 3911: 2139-2146
61. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992; 132: 107-112
62. Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 523: 473-478 (Pubitemid 29075590)
63. Kanda T, Kurokawa M, Tamura S, Nakamura J, Ishii A, Kuwana Y, et al. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 1996; 5919: 1607-1616 (Pubitemid 26358291)
64. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 376: 539-543 (Pubitemid 26169188)
65. McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr., Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 1602: 255-261
66. Calabrese JR, Keck PE, Jr., McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 213: 340-342 (Pubitemid 32452941)
67. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 1984; 2282: 523-530 (Pubitemid 14190765)
68. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltagedependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 1991; 405: 756-765
69. Tomaselli GF, Marban E, Yellen G. Sodium channels from human brain RNA expressed in Xenopus oocytes. Basic electrophysiologic characteristics and their modification by diphenylhydantoin. J Clin Invest 1989; 835: 1724-1732 (Pubitemid 19124131)
70. Ramamoorthy R, Radhakrishnan M, Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008; 191: 29-40.
71. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 292: 126-133 (Pubitemid 38570217)
72. Redrobe JP, Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997; 3252-3: 129-135 (Pubitemid 27199561)
73. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008; 1951: 198-213.
74. Chenu F, Mansari ME, Blier P. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol 2008: 1-11.
75. Wasserman D, Geijer T, Rozanov V, Wasserman J. Suicide attempt and basic mechanisms in neural conduction: relationships to the SCN8A and VAMP4 genes. Am J Med Genet B Neuropsychiatr Genet 2005; 133B1: 116-119
76. Frank B, Niesler B, Nothen MM, Neidt H, Propping P, Bondy B, et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004; 131B1: 1-5. (Pubitemid 39458429)
77. Wang SY, Wang GK. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. Cell Signal 2003; 152: 151-159
78. Cestele S, Catterall WA. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 2000; 829-10: 883-892 (Pubitemid 30843369)
79. Errington AC, Stohr T, Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem 2005; 51: 15-30. (Pubitemid 40202107)